M. Kaye Edward's Insider Trades & SAST Disclosures
M. Kaye Edward's most recent trade in Stoke Therapeutics Inc was a trade of 216,000 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern M. Kaye Edward.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 216,000 | 216,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 144,000 | 144,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 18 Mar 2025 | 10,382 | 148,253 (0%) | 0% | 8.7 | 90,012 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 8.27 per share. | 18 Mar 2025 | 8,907 | 139,346 (0%) | 0% | 8.3 | 73,661 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 35,500 | 132,385 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 35,500 | 71,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 26,250 | 158,635 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 26,250 | 78,750 | - | - | Restricted Stock Units | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 48.93 per share. | 02 Jan 2025 | 255 | 25,637 (0%) | 0% | 48.9 | 12,477 | Common Stock |
| Stoke Therapeutics Inc | M. Kaye Edward | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 30 Dec 2024 | 35,000 | 96,885 (0%) | 0% | 0.6 | 21,000 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 35,000 | 567,801 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Dec 2024 | 6,786 | 61,885 (0%) | 0% | 13.0 | 88,158 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.78 per share. | 06 Dec 2024 | 6,170 | 68,671 (0%) | 0% | 12.8 | 78,837 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 52,500 | 52,500 | - | - | Performance Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 26,250 | 26,250 | - | - | Performance Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 26,250 | 74,841 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 21,591 | 4,317 | - | - | Restricted Stock Unit (RSU) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 21,591 | 48,591 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 52.60 per share. | 01 Oct 2024 | 237 | 25,382 (0%) | 0% | 52.6 | 12,466 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 228 | 25,145 (0%) | 0% | 0 | Common Stock | |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 13,489 | 13,489 | - | - | Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.39 per share. | 20 May 2024 | 39,686 | 29,664 (0%) | 0% | 15.4 | 610,783 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.05 per share. | 20 May 2024 | 2,664 | 27,000 (0%) | 0% | 16.0 | 42,746 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 5,600 | 24,917 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 3,636 | 3,636 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 159,000 | 159,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 105,000 | 105,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 35,500 | 80,500 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 35,500 | 106,500 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 11,150 | 69,350 (0%) | 0% | 6.1 | 67,999 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 84.12 per share. | 02 Jan 2024 | 148 | 19,317 (0%) | 0% | 84.1 | 12,450 | Common Stock |
| Stoke Therapeutics Inc | Kaye M. Edward | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 200,800 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Kaye M. Edward | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 25,908 | 25,908 | - | - | Restricted Stock Unit (RSU) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 33.36 per share. | 03 Jul 2023 | 374 | 18,721 (0%) | 0% | 33.4 | 12,477 | Common Stock |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 10,000 | 10,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 5,000 | 18,347 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 37.71 per share. | 03 Apr 2023 | 298 | 13,347 (0%) | 0% | 37.7 | 11,238 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 213,000 | 213,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 142,000 | 142,000 | - | - | Restricted Stock Unit (RSU) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 44.35 per share. | 03 Jan 2023 | 253 | 13,049 (0%) | 0% | 44.4 | 11,221 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 51.11 per share. | 03 Oct 2022 | 220 | 12,796 (0%) | 0% | 51.1 | 11,244 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 05 Aug 2022 | 11,428 | 12,576 (0%) | 0% | 50 | 571,400 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.75 per share. | 05 Aug 2022 | 11,428 | 24,004 (0%) | 0% | 8.8 | 99,995 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 11,428 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 41.00 per share. | 01 Jul 2022 | 274 | 12,576 (0%) | 0% | 41 | 11,234 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 15,000 | 622,801 | - | - | Employee Stock Option (right to buy) | |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 25 May 2022 | 15,000 | 25,000 (0%) | 0% | 0.6 | 9,000 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 38.38 per share. | 01 Apr 2022 | 293 | 7,302 (0%) | 0% | 38.4 | 11,245 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 308,000 | 308,000 | - | - | Employee Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 46.00 per share. | 03 Jan 2022 | 244 | 7,009 (0%) | 0% | 46 | 11,224 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 23 Dec 2021 | 15,000 | 6,765 (0%) | 0% | 45 | 675,000 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 15,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.61 per share. | 23 Dec 2021 | 15,000 | 21,765 (0%) | 0% | 7.6 | 114,150 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 36.74 per share. | 01 Oct 2021 | 306 | 6,765 (0%) | 0% | 36.7 | 11,242 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 19.78 per share. | 07 Jul 2021 | 63 | 6,459 (0%) | 0% | 19.8 | 1,246 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 20.98 per share. | 01 Jul 2021 | 476 | 6,396 (0%) | 0% | 21.0 | 9,986 | Common Stock |
| Avidity Biosciences Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 10,000 | 10,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 5,000 | 5,920 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 24.44 per share. | 01 Apr 2021 | 409 | 920 (0%) | 0% | 24.4 | 9,996 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 200,800 | 200,800 | - | - | Employee Stock Option (Right to Buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 19.56 per share. | 04 Jan 2021 | 511 | 511 (0%) | 0% | 19.6 | 9,995 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 17 Dec 2020 | 19,806 | 5,194 (0%) | 0% | 60 | 1,188,360 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 17 Dec 2020 | 5,194 | 0 (0%) | 0% | 60 | 311,640 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 27 Nov 2020 | 12,152 | 25,000 (0%) | 0% | 50 | 607,600 | Common Stock |
| Stoke Therapeutics Inc | Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 25 Nov 2020 | 12,848 | 37,152 (0%) | 0% | 50 | 642,400 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 05 Oct 2020 | 20,000 | 0 (0%) | 0% | 30 | 600,000 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2020 | 20,000 | 15,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Cytokinetics Inc | Edward M. Kaye | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.61 per share. | 05 Oct 2020 | 20,000 | 20,000 (0%) | 0% | 7.6 | 152,200 | Common Stock |
| Cytokinetics Inc | Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2020 | 20,000 | 20,000 | - | - | Non-Qualified Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges